What is ALIDC?
The Australian Lead Identification Consortium (ALIDC) was established to provide all Australian drug discovery organisations with open access to a purpose-built screening library of 200,000+ compounds. The drug discovery library is a collection of carefully curated chemistry that is designed to cover the diversity of drug-like chemistry space, and provide tractable starting points for medicinal chemistry optimisation.
Consortium Members
ALIDC is a collaborative consortium that includes Canthera Discovery (CTx CRC Ltd), UniQuest Pty Limited (UniQuest), Walter & Eliza Hall Institute (WEHI), Children’s Cancer Institute Australia for Medical Research (CCIA) and Griffith University (GU). Each ALIDC member organisation has a strong commitment to small molecule drug discovery and along with MTPConnect and Therapeutic Innovation Australia has contributed funds and resources to build and run this essential infrastructure and make it available to the wider Australian drug discovery community.
Contributions
The ALIDC venture has received funding through the following bodies:
MTPConnect Project Fund Program – a dollar-for-dollar matched program investing in big, bold ideas to improve the productivity, competitiveness and innovative capacity of Australia’s medical technology, biotechnology and pharmaceutical sector. MTPConnect is supported by the Australian Government Industry Growth Centres Initiative – learn more at mtpconnect.org.au
Therapeutic Innovation Australia – to support the lodgement and reformatting of the compound libraries into Compounds Australia (one of TIA's Small Molecule Capabilities). TIA is supported by the Australian Department of Education, Skills and Employment through the National Collaborative Research Infrastructure Strategy (NCRIS) program - learn more at https://www.therapeuticinnovation.com.au/
